

Remarks

Claims 1, 3-5, and 7-10 were pending in the subject application. By this Amendment, claim 1 has been amended. The undersigned avers that no new matter is introduced by this amendment. Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 1, 3-5, and 7-10 are currently before the Examiner for consideration. Favorable consideration of the pending claims is respectfully requested.

By this Amendment, Figure 6A has been amended. The figure legend incorrectly had a black box representing 100  $\mu$ M DMXB plus TC-2403. The applicant submits herewith a replacement drawing sheet containing Figures 6A and 6B. As shown in the marked-up version, the black box has been replaced with an appropriate cross-hatch box. This error and the appropriate correction are obvious from the bar graphs of Figures 6A and 6B, and paragraph 0020 at page 8, and paragraph 0065 at page 24, of the specification. The applicant respectfully submits that no new matter has been incorporated into these formal drawings.

By this Amendment, claim 1 has been amended to delete acetylcholine from the recited Markush group.

Claims 1, 3-5, and 7-10 remain rejected under 35 U.S.C. §103(a) as being obvious over Crooks *et al.* (U.S. Patent No. 5,616,707) in view of Newhouse *et al.* (*Society of Biol. Psych.*, 2001, 49:268-278). The applicant respectfully submits that the claimed invention is not obvious over the cited references.

At page 4, the Office Action states that it is not clear from the patent application that the recovery after DMXB (also known as GTS-21 or 3-[2,4-dimethoxybenzylidene]-anabaseine) plus TC-2403 (metanicotine) is greater than the additive effect of each individual compound (DMXB or metanicotine) since there is no experimental data presented on metanicotine alone. Submitted herewith for the Examiner's consideration is a Declaration under 37 C.F.R. §1.132 by Dr. Roger Papke. As explained by Dr. Papke in his Declaration, ABT-418 and DMXB produce varying amounts of residual inhibition (or protracted desensitization), making them in fact mixed agonists-antagonists, as described in paragraphs 0026 and 0027 of the patent application. Thus, while their agonist activity makes compounds such as ABT-418 and DMXB candidate drugs for CNS disorders,

their usefulness would be limited by their residual antagonist activity, which restricts their effectiveness and potentially would compromise other functions mediated by receptors in the brain and peripheral nervous system.

As Dr. Papke explains at page 15, lines 10-14, of his Declaration, Figure 3B of the patent application shows the concentration-response relationship for the recovery of control (the neurotransmitter acetylcholine (ACh)) response amplitude after application of DMXB alone at the indicated concentrations (and Figure 3B of Papke, *JPET* 301:765-773, 2002, which was submitted with the applicant's previous Amendment). ACh is the endogenous agonist for nicotinic acetylcholine receptors. Figures 3C and 3D of the application show the effect of metanicotine alone on alpha3beta4 receptors. Dr. Papke notes "as shown in Figures 3C and 3D, respectively, metanicotine produces very little activation or desensitization of these ganglionic type receptors by itself (also shown in Figures 3C and 3D of Papke, 2002, and Table 2 and Figures 2C and 2F of Papke *et al.*, *J. Neurochem.*, 75:204-216, 2000, which was submitted with the applicant's previous Amendment)".

As Dr. Papke states in his Declaration at page 15, lines 19-28, and page 16, lines 1-3:

An unexpected finding is that co-application of metanicotine with DMXB reduces the inhibitory effects that would otherwise result from application of DMXB alone. Figure 6A shows fractional recovery of the control (acetylcholine) response when oocytes expressing wild-type alpha3beta4 receptors were treated with DMXB alone (solid white bar, far left) or in the presence of metanicotine (cross-hatch bar, far right) (also shown in Figure 6A of Papke, 2002). Only co-application of metanicotine decreased the residual inhibition measured after application of DMXB. As is evident from the graph of Figure 3D of the patent application, if the recovery of the control response for metanicotine alone were to be presented in the bar graph of Figure 6A (e.g., next to DMXB alone), it would show a response of approximately 1.0, neither activating nor inhibiting the alpha3beta4 receptor. Thus, application of metanicotine does not just not inhibit the alpha3beta4 receptor, it actually protects the alpha3beta4 receptor from the residual inhibition that would otherwise occur upon application of DMXB or other mixed agonist-antagonists, such as ABT-418. This is not an additive effect.

As indicated by Dr. Papke, if graphed in Figure 6A of the application, metanicotine alone would neither activate nor inhibit the receptor. However, when co-applied with the mixed agonist-antagonist, metanicotine does not merely fail to inhibit the receptor, it actually protects the receptor from the residual inhibition of the mixed agonist-antagonist. Therefore, if DMXB were administered

for the purpose of stimulating alpha3beta4 receptors in the CNS, co-administration of metanicotine would have a synergistic activity, reducing the peripheral side effects of DMXB (or other mixed agonist-antagonists) alone. As Dr. Papke indicates at page 16, lines 4-10, of his Declaration, metanicotine has virtually no effects on alpha3beta4 receptors (Papke 2000) and “this ability of metanicotine to protect alpha3beta4 nAChR function from long-term inhibition by antagonists or mixed agonists-antagonists was not previously recognized in the scientific literature, and would not have been expected based upon the activities of metanicotine and the other compounds, individually”. The observation that protection from inhibition was provided by a drug that lacks intrinsic inhibitory activity would be unexpected to those of ordinary skill in the art.

Furthermore, Dr. Papke explains in his Declaration that the surprising ability of metanicotine to protect nAChR from the inhibitory after-effects of other potentially therapeutic compounds is significant, clinically. For example, metanicotine can be co-administered with other potentially therapeutic mixed agonists-antagonists that may otherwise be disqualified for therapeutic use due to their inhibitory side effects. As Dr. Papke states in his Declaration at page 16, lines 18-22, examples of side effects that would be expected include “vasoconstriction, constipation, pupil dilation, xerostenia (dry mouth), loss of accommodation (focusing ability), urine hesitancy and retention, impotence, anorexia, eructation (belching), and orthostatic hypotension.”

It is well settled in patent law that “a greater than expected result is an evidentiary factor pertinent to the legal conclusion of obviousness … of the claims at issue” *In re Corkill*, 226 USPQ 1005 (Fed. Cir. 1985). Evidence of a greater than expected result may be shown by demonstrating an effect which is greater than the sum of each of the effects taken separately (*i.e.*, demonstrating “synergism”). *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 10 USPQ2d 1843 (Fed. Cir.), *cert. denied*, 493 U.S. 975 (1989). Furthermore, the presence of a property not possessed by the prior art is evidence of nonobviousness. *In re Papesch*, 137 USPQ 43 (C.C.P.A. 1963).


The benefits of the claimed method are unexpected in view of the prior art, and have a significant, practical advantage. Therefore, the applicant respectfully submits that the claimed invention is not obvious over the prior art. In view of the foregoing remarks, reconsideration and withdrawal of the rejection under 35 U.S.C. §103(a) is respectfully requested.

In view of the foregoing remarks and amendments to the claims, the applicant believes that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Glenn P. Ladwig  
Patent Attorney  
Registration No. 46,853  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 NW 41st Street, Suite A-1  
Gainesville, FL 32606-6669

GPL/mv

Attachments: Petition and Fee for Extension of Time  
Declaration by Dr. Papke under 37 C.F.R. §1.132  
Replacement Drawing Sheet  
Marked-up Drawing Sheet



Patent Application  
Docket No. UF-293  
Serial No. 10/036,988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Brian Yong S. Kwon  
Art Unit : 1614  
Applicant : Roger L. Papke  
Serial No. : 10/036,988  
Filed : December 31, 2001  
For : Compositions and Methods for Treatment of Neurological Disorders

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF ROGER L. PAPKE, Ph.D., UNDER 37 C.F.R. §1.132

Sir:

I, Roger L. Papke, Ph.D., of the University of Florida, Department of Pharmacology and Therapeutics, hereby declare:

THAT, I am the named inventor on the above-referenced patent application;

THAT, I have received the following degrees:

Ph.D. Neurobiology and Behavior	1987	Cornell University, Ithaca, NY
M.S. Physiology	1976	New York University, NY, NY
B.A. Biology and Classics	1975	New York University, NY, NY

THAT, I have been employed professionally as follows:

1987	Postdoctoral Research Associate: Department of Pharmacology, Cornell University
1987	Lecturer: Department of Neurobiology and Behavior, Cornell University

1988-1993	Postdoctoral Research Fellow: Molecular Neurobiology Laboratory, Salk Institute
1993-1998	Assistant Professor: Department of Pharmacology and Therapeutics, University of Florida
1994-1998	Affiliate Assistant Professor: Department of Neuroscience University of Florida
1998-present	Associate Professor: Department of Pharmacology and Therapeutics, University of Florida
1998-present	Affiliate Associate Professor: Department of Neuroscience University of Florida

THAT, I have published extensively in my field and some of the publications are as follows:

1. Roger L. Papke and Robert E. Oswald. 1986. Effects of allosteric ligands on the gating of single channel currents in bc3h-1 cells. N.A.T.O. *Advanced Research Workshop Mechanism of Action of The Nicotinic Acetylcholine Receptor*, Santorini, Greece. NATO ASI Series Vol. H3 Ed. A. Maelicke Springer-Verlag, Berlin.
2. S. Heinemann, J. Boulter, E. Deneris, J. Connelly, R. Duvoisin, R. Papke, and J. Patrick. 1989. The brain nicotinic acetylcholine receptor gene family. *Cell and Molecular Biology of Neuroplasticity in Aging and Alzheimer's Disease, Conference Proceedings*. Bethesda, Maryland, May 1-3, 1989.
3. S. Heinemann, J. Boulter, J. Connelly, E. Deneris, R. Duvoisin, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, A. O'Shea-Greenfield, R. Papke, S. Rogers, and J. Patrick. 1989. The brain nicotinic receptor genes. *Molecular Approaches to Drug Abuse Research. N.I.D.A. Conference Proceedings*. Bethesda, Maryland, August 24-25, 1989.
4. S. Heinemann, J. Boulter, J. Connelly, E. Deneris, R. Duvoisin, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, A. O'Shea-Greenfield, R. Papke, S. Rogers, and J. Patrick. 1989. The nicotinic receptor genes. *Hoechst-Roussel Pharmaceuticals Research Seminar. Conference Proceedings*. Hershey Pennsylvania, October 25, 1989.
5. Roger L. Papke. 1993. The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. *Progress in Neurobiology* 41:509-531.

6. Roger L. Papke, Christopher M. de Fiebre, William Kem, and Edwin M. Meyer. 1994. The subunit specific effects of novel anabaseine-derived nicotinic agents. Proceedings of the Third International Springfield Alzheimer Symposium. Springfield Illinois May 11- 15 1994. Editors: E. Giacobini and R. Becker. Birkhauser Boston publishers.
7. R.H. Lenox, R.K. McNamara, R.L. Papke and H. Manji, 1998. Neurobiology of lithium: an update. *Journal of Clinical Psychiatry*, 58(supplement 6): 37-47.
8. Anatoli Y. Kabakov and Roger L. Papke, 1998. Ultra fast solution applications for prolonged gap-free recordings: Controlling a Burleigh piezo-electric positioner with Clampex7. *Axobits* Jan. 1998 24:6-9.
9. Michael M. Francis, and Roger L. Papke, 2000. The functional diversity of nicotinic receptors in the nervous system: perspectives on receptor subtypes and receptor specialization *Handbook of Experimental Pharmacology* 144: 301-336.
10. Roger L. Papke, 1999. Single channel analysis in pClamp 8. *Axobits* October. 1999 27:7-12.
11. Roger L. Papke, 1999. Neuronal Nicotinic Receptors: From Structure to Therapeutics. Meeting report. *Investigational Drugs, weekly highlights*. 48:37-41
12. Roger L. Papke and Julia K. Porter Papke. 2002. The Use of Net-Charge Analysis for the Study of Ion Channel Pharmacology. *Axobits* November 2002 36:6-9
13. Roger L. Papke, Patrick W. Concannon, Hugh F. Travis and William Hansel. 1980. Control of luteal function and implantation in the mink by prolactin. *Journal of Animal Science* 50(6):1102-1107.
14. Roger L. Papke, Tom R. Podleski and Robert Oswald. 1986. Effects of pineal factors on the action potentials of sympathetic neurons. *Cellular and Molecular Neurobiology* 6(4):381-396.
15. Roger L. Papke, Glenn Millhauser, Zorba Lieberman and Robert Oswald. 1988. Relationships of agonist properties to the activation kinetics of nicotinic acetylcholine receptors. *Biophysical Journal* 53(1):1-10.
16. Robert E. Oswald, Roger L. Papke and Ronald J. Lukas. 1989. Characterization of nicotinic acetylcholine receptor channels of the TE671 human medulloblastoma cell line. *Neuroscience letters*. 96:207-212.

17. Roger L. Papke and Robert E. Oswald. 1989. Mechanisms of noncompetitive inhibition of acetylcholine-induced single channel currents. *Journal of General Physiology* 93:785-811.
18. Roger L. Papke, Jim Boulter, Jim Patrick, and Steve Heinemann. 1989. Single channel currents of rat neuronal nicotinic acetylcholine receptors expressed in *Xenopus laevis* oocytes. *Neuron* 3(5):589-596.
19. Scott W. Rogers, Lorise C. Gahring, Roger L. Papke, and Stephen Heinemann. 1991. Identification of cultured cells expressing ligand-gated cationic channels. *Protein Expression and Purification* 2:108-116.
20. Roger L. Papke, and Steve F. Heinemann. 1991. The role of the  $\beta 4$  subunit in determining the kinetic properties of rat neuronal nicotinic acetylcholine  $\alpha 3$  receptors. *Journal of Physiology, London* 440:95-112.
21. Roger L. Papke, Robert M. Duvoisin, and Stephen F. Heinemann. 1993. The amino terminal half of the nicotinic  $\beta$  subunit extracellular domain regulates the kinetics of inhibition by neuronal-bungarotoxin. *Proceedings of the Royal Society, (London), Series B* 252:141-147.
22. Roger L. Papke, and Steve F. Heinemann. 1994. The partial agonist properties of cytisine on neuronal nicotinic receptors containing the  $\beta 2$  subunit. *Molecular Pharmacology* 268:718-726.
23. Roger L. Papke, A. Grey Craig, and Steve F. Heinemann. 1994. Inhibition of nicotinic acetylcholine receptors by bis (2, 2, 6, 6 - tetramethyl-4-piperidinyl) sebacate (Tinuvin<sup>®</sup> 770), an additive to medical plastics. *Journal of Pharmacology and Experimental Therapeutics* 268:718-726.
24. Bruce E. Hunter, Christopher M. de Fiebre, Roger L. Papke, William R. Kem, and Edwin M. Meyer. 1994. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. *Neuroscience Letters* 168:130-134.
25. Christopher M. de Fiebre, Edwin M. Meyer, Jeffrey C. Henry, Samuel I. Muraskin, William R. Kem and Roger L. Papke. 1995. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative (DMAC) is a selective agonist at neuronal nicotinic  $\alpha 7/[125\text{i}]$ -bungarotoxin receptor subtypes. *Molecular Pharmacology* 47:164-171.

Docket No. UF-293  
Serial No. 10/036,988

26. D.H. Feldman, J.S. Thinschmidt, A.L. Peel, R. L. Papke, and P.J. Reier. 1996. Differentiation of ionic currents in CNS progenitor cells: Dependence upon substrate attachment and epidermal growth factor. *Experimental Neurology* 140(2):206-17.
27. Michael M. Francis and Roger L. Papke. 1996. Muscle-type nicotinic acetylcholine receptor delta subunit determines sensitivity to noncompetitive inhibitors while gamma subunit regulates divalent permeability. *Neuropharmacology* 35:1547-1556.
28. R. L. Papke, M. Bencherif, and P. Lippiello. 1996. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the  $\alpha 7$  subtype. *Neuroscience Letters* 213:201-204.
29. R. L. Papke, J. S. Thinschmidt, B. A. Moulton, E. M. Meyer, and A. Poirier. 1996. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. *British Journal of Pharmacology* 120:429-438.
30. William R. Kem, Vladimir M. Mahnir, Roger L. Papke and Christopher J. Lingle. 1997. Anabaseine is a potent agonist upon muscle and neuronal alpha-bungarotoxin sensitive nicotinic receptors. *Journal of Pharmacology and Experimental Therapeutics*, 283:979-992.
31. E. M. Meyer, E. T. Tay, R. L. Papke, C. Meyers, G. Huang, and C. M. de Fiebre. 1997. Effects of 3-[2,4-dimethoxybenzylidene]anabaseine (DMXB) on rat nicotinic receptors and memory-related behaviors. *Brain Research*, 768(1-2):49-56.
32. Anatolii Y. Kabakov, Nikolas B. Karkanias, Robert H. Lenox, and Roger L. Papke. 1998. Synapse specific accumulation of lithium in intracellular microdomains: A model for uncoupling coincidence detection in the brain. *Synapse*, 28:271-279
33. M. M. Francis, K. Il Choi, B. A. Horenstein and R. L. Papke. 1998. Sensitivity to voltage-independent inhibition determined by pore-lining region of ACh receptor. *Biophysical Journal*, 74:2306-2317
34. Edwin M. Meyer, Ee Tein Tay, John A. Zoltewicz, Roger L. Papke, Craig Meyers, Mike King, and Christopher M. de Fiebre. 1998. Neuroprotective and memory-related actions of novel  $\alpha 7$  nicotinic agents with different mixed agonist/antagonist properties. *Journal of Pharmacology and Experimental Therapeutics* 284:1026-1032
35. Edwin Meyer, Alexander Kuryatov, Volodymyr Gerzanich, Jon Lindstrom and Roger L. Papke. 1998. Analysis of 40H-GTS-21 Selectivity and Activity at Human and Rat  $\alpha 7$ -Nicotinic Receptors. *Journal of Pharmacology and Experimental Therapeutics*, 287(3):918-25

36. Jose R. Gomez, Nikolas B. Karkanias, Robert H. Lenox, and Roger L. Papke. 1998. Lithium Homeostasis In *Xenopus* Oocytes: Implications For The Study Of Signal Transduction. *Life Sciences* 63(19):1715-1724.
37. Roger L. Papke, and Jeffrey S. Thinschmidt. 1998. The Correction of Alpha7 Nicotinic Acetylcholine Receptor Concentration-Response Relationships in *Xenopus* Oocytes. *Neuroscience Letters* 256(3):163-166.
38. Yangxin Li, Roger L. Papke, Yun-Ju He, Bill Millard, and Edwin M. Meyer . 1999. Characterization of the neuroprotective and toxic effects of  $\alpha 7$  nicotinic receptor activation in PC12 cells. *Brain Research*, 830(2):218-25.
39. Nikolas B. Karkanias and Roger L. Papke.1999. Subtype specific effects of lithium on Glutamate receptor function. *Journal of Neurophysiology*, 81(4):1506-12
40. J. Christopher Webster, Michael M. Francis, Julia K. Porter, Gillian Robinson, Clare Stokes, Ben Horenstein, and Roger L. Papke, 1999. Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain. *British Journal of Pharmacology*, 127:1337-48.
41. Nikolas B. Karkanias and Roger L. Papke, 1999. Lithium Modulates Desensitization of the Glutamate Receptor Subtype GluR3. *Neuroscience Letters*, 277(3):153-6..
42. Roger L. Papke, Edwin Meyer, Tom Nutter, and Vladimir V. Uteshev , 2000. Alpha7-selective agonists and modes of alpha7 receptor activation. *European Journal of Pharmacology*, 393(1-3):179-195
43. Roger L. Papke, J. Christopher Webster, Patrick M. Lippiello Merouane Bencherif, and Michael M. Francis. 2000. The activation and inhibition of human nAChR by RJR-2403 indicate a selectivity for the  $\alpha 4\beta 2$  receptor subtype. *Journal of Neurochemistry* 75(1)204-216.
44. M. M. Francis, R. W. Vazquez, R. L. Papke, and R. E. Oswald. 2000 Subtype-selective inhibition of neuronal nAChRs by cocaine is determined by the alpha4 and beta4 subunits. *Molecular Pharmacology*, 58(1):109-19.
45. Roger L. Papke, Paul R. Sanberg, R. Douglas Shytle, 2001. Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes. *Journal of Pharmacology and Experimental Therapeutics*, 297:646-656.

Docket No. UF-293  
Serial No. 10/036,988

46. Roger L. Papke, Benjamin A. Horenstein, and Andon N. Placzek 2001. Inhibition of Wild-Type and Mutant Neuronal Nicotinic Acetylcholine Receptors by Local Anesthetics. *Molecular Pharmacology* 60(6):1365-1374.
47. Simon M. N. Efange, Zhude Tu, Krystyna von Hohenberg, Lynn Francesconi, Robertha C. Howell, Marilyn V. Rampersad, Louis J. Todaro, Roger L. Papke, and Mei-Ping Kung. 2001. 2-(2-Piperidyl)- and 2-(2-Pyrrolidyl)chromans as Nicotine Agonists: Synthesis and Preliminary Pharmacological Characterization. *Journal of Medicinal Chemistry* 44(26):4704-4715.
48. Roger L. Papke 2002. Enhanced inhibition of a mutant neuronal nAChR by agonists: protection of function by TC-2403. *Journal of Pharmacology and Experimental Therapeutics* 301(2):765-73.
49. Daisuke Takeda, Terumasa Nakatsuka, Roger Papke, Jianguo Gu 2003 Modulation of inhibitory synaptic activity by a non- $\alpha 4\beta 2$ , non- $\alpha 7$  subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord. *Pain* 101:13-23
50. Vladimir V. Uteshev, Edwin M. Meyer and Roger L. Papke. 2002 Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. *Brain Research*, 948(1-2):33-46.
51. Roger L. Papke and Julia K. Porter Papke. 2002 Comparative pharmacology of rat and human  $\alpha 7$  nAChR conducted with net charge analysis. *British Journal of Pharmacology* 137(1):49-61.
52. Vladimir V. Uteshev, Edwin M. Meyer, and Roger L. Papke. 2003 Regulation of neuronal function by choline and 4OH-GTS-21 through alpha7 nicotinic receptors. *Journal of Neurophysiology*, 89(4):1797-1806.
53. Charles J. Frazier, Ben W. Stowbridge, and Roger L. Papke. 2003 Nicotinic acetylcholine receptors on local circuit neurons in the dentate gyrus: a potential role in the regulation of granule cell excitability. *Journal of Neurophysiology*, 89(6):3018-28.
54. Patrick W. Concannon, Tom Pilbeam, Roger L. Papke, Hugh Travis. 1978. Annual reproductive cycle of the mink (*Mustela vison*). *Program of the Annual Conference of the Society for the Study of Fertility*. Page 20, Cambridge.
55. Roger L. Papke and Robert E. Oswald. 1986. Effects of tetracaine on the burst durations and voltage dependence of nicotinic acetylcholine receptors from BC3H-1 cells. *16th Annual Meeting of the Society for Neuroscience*.

Docket No. UF-293  
Serial No. 10/036,988

56. Roger L. Papke, Glenn Millhauser, Zorba Lieberman and Robert Oswald. 1987. The relationship of agonist properties to the activation kinetics of the nicotinic acetylcholine receptor. *17th Annual Meeting of the Society for Neuroscience*.
57. R.E. Oswald, R.L. Papke and R.J. Lukas. 1988. Characterization of nicotinic acetylcholine receptor channels of the TE671 human medulloblastoma cell line. *32nd Annual Meeting of the Biophysical Society*.
58. Steve Heinemann, Jim Boulter, Evan Deneris, John Connelly, Roger Papke, Etsuko Wada, Keiji Wada, Marc Ballivet, Larry Swanson, and Jim Patrick. 1988. The nicotinic acetylcholine receptor gene family. *N.A.T.O. Advanced Research Workshop on Nicotinic Acetylcholine Receptors in the Nervous System*. Venice, Italy, April 1988.
59. R. L. Papke, R. Duvoisin, J. Boulter, and S. Heinemann. 1989. The possible importance of the neuronal nicotinic subunit  $\beta_4$  to the kinetic properties of the adrenal chromaffin cell AChR. *19th Annual Meeting of the Society for Neuroscience*. 333.12
60. Jim Boulter, John Connelly, Evan Deneris, Robert Duvoisin, Roger Papke, Jim Patrick and Steve Heinemann 1989. Molecular biology of neuronal nicotinic acetylcholine receptors. *International Brain Research Organization and The Israel Academy of Sciences and Humanities Symposium on Cellular Neurobiology: Ions, Molecules, and Genes*. Jerusalem, Israel. October 23-25, 1989
61. S. Heinemann, J. Boulter, J. Connelly, E. Deneris, R. Duvoisin, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, D. Johnson, A. O'Shea-Greenfield, R. Papke, and S. Rogers 1990. The glutamate and nicotinic receptor genes. *The 34th annual meeting of The Biophysical Society*. Baltimore, MD February 18-22 1990. *Biophysical J.* 57:Tu-AM-Sym I-1.
62. S. Heinemann, B. Bettler, J. Boulter, E. Deneris, R. Duvoisin, G. Gasic, M. Hartley, I. Hermans-Borgmeyer, M. Hollmann, D. Johnson, A. O'Shea-Greenfield, R. Papke, and S. Rogers 1990. The glutamate receptor gene family. *The Cold Springs Harbor 55th Symposium on Quantitative Biology: The Brain*. Cold Springs Harbor, N.Y. May 30-June 6, 1990.
63. B. Bettler, J. Boulter, E. Deneris, I. Hermans-Borgmeyer, A. O'Shea-Greenfield, M. Hartley, C. Moll, R. Papke, and S. Heinemann. 1990. Molecular structure and expression of rat glutamate receptors. *20th Annual Meeting of the Society for Neuroscience*.

Docket No. UF-293  
Serial No. 10/036,988

64. Roger L. Papke, Robert Duvoisin, and Stephen F. Heinemann. 1991. The extracellular domain of the neuronal nicotinic subunit  $\beta 4$  determines the pharmacology of receptors formed with  $\alpha 3$ . *21st Annual Meeting of the Society for Neuroscience*. 534.12
65. W. R. Kem and R. L. Papke. 1992. Action of anabaseine and DMAB-anabaseine upon the  $\alpha 4\beta 2$  and PC12 cell nicotinic receptors. *22nd Annual Meeting of the Society for Neuroscience*. 569.19
66. Roger L. Papke. 1993. Use-dependent inhibition of neuronal nicotinic AChR by Timuvin® 770 (bis (2, 2, 6, 6, - tetramethyl-4-piperidinyl) sebacate), A possible additive to laboratory plastics. *37th Annual Meeting of the Biophysical Society*. 64: WED P-421
67. Roger L. Papke, Christopher M. de Fiebre, Bruce E. Hunter, William R. Kem, and Edwin M. Meyer. 1993. DMXB, a novel nicotinic ligand which modulates hippocampal LTP, has agonist and antagonist effects on nicotinic  $\alpha 7$  receptors. *23rd Annual Meeting of the Society for Neuroscience*. 120.8
68. Roger L. Papke, Wayne Gottlieb, Ben Horenstein, and Michael Francis. 1994. Bridging the nicotinic acetylcholine receptor channel: prolonged inhibition associated with use-dependent binding of a bi-functional inhibitor. *24th Annual Meeting of the Society for Neuroscience*. 463.12
69. C.M. de Fiebre, R.L. Papke and E.M. Meyer. 1995. Effects of ethanol on neuronal nicotinic receptors expressed in *Xenopus* oocytes. *25th Annual Meeting of the Society for Neuroscience*. 206.8
70. D.H. Feldman, J.S. Thinschmidt, A.L. Peel, R.L. Papke, and P.J. Reier. 1995. Differentiation of ionic currents in CNS progenitor cells. *25th Annual Meeting of the Society for Neuroscience*. 122.5
71. R.L. Papke, C.M. de Fiebre, B.A. Moulton, J.S. Thinschmidt, R. Quintana, and E.M. Meyer. 1995. Activation and inhibition of neuronal nAChRs by potential therapeutic agents. *25th Annual Meeting of the Society for Neuroscience*. 247.14
72. M. M. Francis, R. Quintana, and R.L. Papke 1995. Common structural determinants of physiological and pharmacological properties in nAChR. *25th Annual Meeting of the Society for Neuroscience*. 36.2
73. N.B. Karkanias, R.H. Lenox, and R.L. Papke. 1995. Interactions between lithium and neuronal nicotinic receptors: Potential significance for the clinical use of lithium. *25th Annual Meeting of the Society for Neuroscience*. 33.19

74. J. Watterson, P. Lippiello, M. Bencherif, and R. L. Papke. 1996 In vitro activation of  $\alpha 4\beta 2$  nAChR by RJR-2403 suggests differential desensitization by nicotine. *26th Annual Meeting of the Society for Neuroscience*. 503.23

75. M. M. Francis, Kyung Choi, Ben Horenstein and R.L. Papke. 1996 The disposition of use-dependent binding sites in nAChR. *26th Annual Meeting of the Society for Neuroscience*. 602.4

76. R.L. Papke, E. M. Meyer, and C.M. de Fiebre. Differential discrimination between human and rat  $\alpha 7$  nAChR by GTS-21 and its primary metabolite, 4-OH,2 methoxybenzylidene anabaseine. *26th Annual Meeting of the Society for Neuroscience*. 602.3

77. Anatolii Y. Kabakov, Nikolas B. Karkanias and Roger L. Papke. Estimation of lithium diffusion in dendritic spines during activation of glutamate receptors. *1997 Biophysical Journal* 72 (2) A118.

78. R.L. Papke, M.M. Francis and J.S. Thinschmidt, Techniques for improved resolution of kinetic data from macroscopic currents. *1997 Biophysical Journal* 72 (2) A41.

79. M.M. Francis, K.S. Clark and R.L. Papke, 1997 Role of  $\alpha 5$  subunit in determining relationship of peak to late-phase current in human  $\alpha 3\beta 2\alpha 5$  neuronal nicotinic acetylcholine receptors. *27th Annual Meeting of the Society for Neuroscience*.

80. K. Sawh and R. L. Papke, 1997. Effects of subunit composition on nicotinic AChR inhibition by hexamethonium and decamethonium: dissociation of sensitivity and mechanism. *27th Annual Meeting of the Society for Neuroscience*.

81. N.B. Karkanias, A.Y. Kabakov and R.L. Papke, 1997. Lithium differentially affects glutamate receptors. *27th Annual Meeting of the Society for Neuroscience*.

82. Anatolii Y. Kabakov and Roger L. Papke, 1998. Kinetics Of BTMPS Block Of Expressed Muscle nAChR in Outside-Out Patches: High Resolution Analysis Of A Slow Process. *Biophysical Journal* 73 (2)

83. R.L. Papke, J. C. Webster, P. M. Lippiello, M. Bencherif, and M. M. Francis, 1998. RJR-2403 is an efficacious agonist for human  $\alpha 4\beta 2$  neuronal nicotinic acetylcholine receptors with lower efficacy for other human receptor subtypes. *28th Annual Meeting of the Society for Neuroscience*. 39.26

84. J.C. Webster, M.M. Francis, and R.L. Papke, 1998. Differential sensitivity to the antagonist effects of mecamylamine and nicotine regulated by the AChR beta subunit TM2 domain. *28th Annual Meeting of the Society for Neuroscience* 332.19.
85. N.B Karkanias and R.L. Papke, 1998. Potential mechanism for the effect of lithium on AMPA receptors. *28th Annual Meeting of the Society for Neuroscience* 44.17
86. E.M. Meyer, Y. Li, W.J. Millard, Y.J. He, and R.L. Papke, 1998. Neuroprotection, neurotoxicity and selective alpha<sub>7</sub> nicotinic receptor activation. *28th Annual Meeting of the Society for Neuroscience*. 331.7
87. Ed Meyer, Viviana Puig, Craig Meyers, Valdimir Uteshev, Tom Nutter and Roger L. Papke, 1999. Selective alpha<sub>7</sub> nicotinic receptor agonists DMXB and 4OH DMXB protect against amyloid toxicity and increase bcl-2 immunoreactivity: role of PKC. *29th Annual Meeting of the Society for Neuroscience*. 394.18.
88. Michael M. Francis, Raymond Vazquez, Roger L. Papke and Robert E. Oswald, 1999. Subtype-selective inhibition of neuronal nicotinic acetylcholine receptors by cocaine. *29th Annual Meeting of the Society for Neuroscience*. 497.13.
89. R.L. Papke, and J. K. Porter, 1999. Potential control of steric and allosteric inhibition by residues in the AChR beta subunit TM2 domain. *29th Annual Meeting of the Society for Neuroscience*. 497.12
90. V. V. Uteshev, E. Meyer and R. L. Papke, 2000. Desensitization kinetics of  $\alpha 7$  neuronal nicotinic receptors of the histamine neurons of the rat hypothalamus. *Biophysical Journal* 75(2): 2116
91. V. V. Uteshev, E. Meyer and R. L. Papke, 2000. Kinetic analysis of  $\alpha 7$  nAChR fast desensitization in acutely dissociated neurons: Implications for therapeutics. *30th Annual Meeting of the Society for Neuroscience*.
92. V. V. Uteshev, E. Meyer, and R. L. Papke, 2000 Kinetic analysis of  $\alpha 7$  nAChR fast desensitization in acutely dissociated hypothalamic neurons: implications for therapeutics. *Benzon Symposium No. 47, Molecular Pharmacology of Ion Channels*. August 13-17, 2000 Copenhagen, Denmark
93. R. L. Papke, P. R. Sanberg, R. D. Shytle, 2000 Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes *Neuronal Nicotinic Receptors - The 10th Neuropharmacology Conference* - November 2-4, 2000 New Orleans, USA

94. Placzek and R. L. Papke, 2001. Modulatory Sites In The Second Transmembrane Domain Of The  $\alpha 7$  nAChR Subunit. *31st Annual Meeting of the Society for Neuroscience*.
95. V.V. Uteshev E.M. Meyer, L. Prokai and R.L. Papke, 2001. Choline Regulates  $\alpha$ -Bungarotoxin Sensitive  $\alpha 7$ -Type Nicotinic Receptor Functioning In A Dynamic Manner In The Hypothalamic Slices. *31st Annual Meeting of the Society for Neuroscience*.
96. M. Nelson, R. Papke, E. Costa, J.I. Javaid, 2001. 3-(4-Hydroxy, 2-Methoxybenzylidene) Anabaseine, A Specific Agonist Of Alpha-7 Homomeric Nicotinic Acetylcholine Receptors, Releases Striatal Dopamine Without Causing A Long Term Inhibition Of DA Release. *31st Annual Meeting of the Society for Neuroscience*.
97. J.H. Graham, R.L. Papke, and J.J. Buccafusco, 2001. Potential Central Activity Of Tinuvin, A Novel Nicotinic Receptor Antagonist. *31st Annual Meeting of the Society for Neuroscience*.
98. R. L. Papke and V. V. Uteshev. Choline regulates the function of CNS neurons via alpha $\gamma$  receptor activation/desensitization. *Third Forum of European Neuroscience 2002 Paris France*. P114
99. R. L. Papke and C. Stokes. Connecting animal studies to therapeutics: defining the structural basis for drug selectivity between human and rat nicotinic receptors. *8<sup>th</sup> International Conference on Alzheimer's Disease and Related Disorders. 2002, Stockholm, Sweden*. P1:435
100. W. Kem, V. Mahnir, L. Prokai, X. Cao, R. L. Papke, J. Porter-Papke, S. Michalski, K. Wildeboer, K. Prokai-Tatrai, F. Soti 2002 Hydroxy metabolites of the Alzheimer's drug candidate DMXBA (GTS-21): A comparison of their chemical properties, brain penetration and interactions with brain nicotinic receptors. *8<sup>th</sup> International Conference on Alzheimer's Disease and Relared Disorders. 2002, Stockholm, Sweden*. P1:455
101. C.J. Frazier, B.W. Stowbridge, and R.L. Papke 2002 Characterization Of Neuronal Nicotinic Acetylcholine Receptors In Rat Dentate Gyrus. *32nd Annual Meeting of the Society for Neuroscience*.
102. R. L. Papke J. K. Papke and C. Stokes. 2002 The structural basis for drug selectivity between human and rat nicotinic alpha $\gamma$  receptors. *32nd Annual Meeting of the Society for Neuroscience*.

103. A Placzek and R. L. Papke 2002 Single TM2 domain point mutations confer properties of beta subunit-containing receptors to mutant  $\alpha 7$  nAChRs *32nd Annual Meeting of the Society for Neuroscience*.
104. R. L. Papke, J. K. Porter-Papke, T. J. McCormack, W.I Kem and C. Stokes. 2003. Alpha $\gamma$  selective agonists and the structural basis for drug selectivity between human and rat nicotinic alpha $\gamma$  receptors. *Neuronal Nicotinic Receptors and Ligands: Targets for Medications NIDA conference CPDD Bal Harbor, Florida*
105. K.M. Wildeboer; S.E. LeFrancois; R.L. Papke; F. Soti; W.R. Kem 2003 Nicotine analogs as selective ligands for  $\beta 2$ -containing nicotinic acetylcholine receptors *33rd Annual Meeting of the Society for Neuroscience*.
106. V. V. Uteshev and R. L. Papke 2003 Analysis of  $\alpha 7$  nicotinic AChR kinetics in the histaminergic nucleus of the posterior hypothalamus. *33rd Annual Meeting of the Society for Neuroscience*.
107. R. L. Papke, M. M. Francis, K. Il Choi, B. A. Horenstein and M. I. Damaj 2003 *In vitro* and *in vivo* characterization of a novel and selective inhibitor of CNS nicotinic receptors. *33rd Annual Meeting of the Society for Neuroscience*.
108. J.S. Thinschmidt C.J. Frazier M.A. King' E.M. Meyer K. WU R.L. Papke. 2003. Hippocampal  $\alpha 7$  nicotinic receptor expression is regulated by septal innervation. *33rd Annual Meeting of the Society for Neuroscience*
109. K. Ren, CA Meyers, C. Stokes, V . Uteshev, R.L. Papke, J.A. Hughes, E.M. Meyer. 2003 Genetic and pharmacological modulation of nicotinic alpha $\gamma$  receptor function. *33rd Annual Meeting of the Society for Neuroscience*
110. M.B. Marrero, R.L. Papke, B.S. Bhatti, S. Shaw, and M. Bencherif. 2003 The neuroprotective effect of tc-1698, a novel alpha $\gamma$  ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. *33rd Annual Meeting of the Society for Neuroscience*.
111. C.J. Frazier, and R.L. Papke 2003. Activation Of  $\alpha 7$  Nicotinic Receptors Can Contribute To Induction Of A Muscarinic Afterdepolarization In Dentate Mossy Cells. *33rd Annual Meeting of the Society for Neuroscience*
112. A.N. Placzek, E. M. Meyer, T.A.S. Papke, & R.L. Papke. 2003. A single residue in the  $\alpha 7$  nicotinic acetylcholine receptor tm2 domain is required for potentiation by 5-hydroxyindole. *33rd Annual Meeting of the Society for Neuroscience*

113. J. Dominy, J. Thinschmidt, J. Peris, R. Dawson, R. L. Papke 2003. An Apparent Dissociation Between Intracellular Taurine Content and Long-Lasting Potentiation in the Rat Hippocampus *33rd Annual Meeting of the Society for Neuroscience*

THAT, through my years of research, I have kept up to date on the technical literature and maintained contact with experts in the field by participating in professional meetings and seminars, and by direct personal contact. As a result, I am familiar with the general level of skill of those working in the fields of molecular biology and pharmacology, and particularly as they relate to nicotinic acetylcholine receptors;

THAT, I have read and understood the specification and claims of the subject application and the Office Actions dated August 26, 2003 and February 26, 2004;

AND, being thus duly qualified, do further declare:

The Office Action dated February 26, 2004 indicates that because the Crooks *et al.* patent teaches the administration of metanicotine (also known as TC-2403, RJR-2403, or (E)-N-methyl-4-(3-pyridinyl)-3-butene-1-amine) to treat Alzheimer's disease (AD) and the Newhouse *et al.* publication teaches the administration of ABT-418 (also known as (S)-3-methyl-S-(1-methyl-2-pyrrolidinyl)isoxazole) to treat AD, it would have been obvious to combine the two therapies to treat AD with enhanced therapeutic effect. Furthermore, at page 4, the Office Action states that it is not clear from the patent application that the recovery after DMXB (also known as GTS-21 or 3-[2,4-dimethoxybenzylidene]-anabaseine) plus metanicotine is greater than the additive effect of each individual compound (DMXB or metanicotine) since there is no experimental data presented on metanicotine alone.

I wish to elaborate on the significance of the discovery that co-administration of metanicotine protects nicotinic acetylcholine receptors (nAChR) in the autonomic nervous system from side effects that would be expected from the administration of mixed agonists-antagonists alone. As explained in the patent application, numerous nicotinic compounds, such as metanicotine, ABT-418, and DMXB, have been characterized as agonists or partial agonists for select nAChR subtypes.

Additionally, with the exception of metanicotine, these compounds produce varying amounts of residual inhibition (or protracted desensitization), making them in fact mixed agonists-antagonists, as described in paragraphs 0026 and 0027 of the patent application. Thus, while their agonist activity makes compounds such as ABT-418 and DMXB candidate drugs for CNS disorders, their usefulness would be limited by their residual antagonist activity, which restricts their effectiveness and potentially would compromise other functions mediated by receptors in the brain and peripheral nervous system.

The ordinarily skilled artisan would expect peripheral side effects from the administration of DMXB (*i.e.*, blocking receptors in autonomic ganglia), based upon its residual inhibitory effects on wild-type alpha<sub>3</sub>beta<sub>4</sub> receptors. This is demonstrated in Figure 3B of the patent application, which shows the concentration-response relationship for the recovery of control (the neurotransmitter acetylcholine (ACh)) response amplitude after application of DMXB alone at the indicated concentrations (and Figure 3B of Papke, *JPET* 301:765-773, 2002). ACh is the endogenous agonist for nicotinic acetylcholine receptors.

Figures 3C and 3D of the application show the effect of metanicotine alone on alpha<sub>3</sub>beta<sub>4</sub> receptors. As shown in Figures 3C and 3D, respectively, metanicotine produces very little activation or desensitization of these ganglionic type receptors by itself (also shown in Figures 3C and 3D of Papke, 2002, and Table 2 and Figures 2C and 2F of Pepke *et al.*, *J. Neurochem.*, 75:204-216, 2000).

An unexpected finding is that co-application of metanicotine with DMXB reduces the inhibitory effects that would otherwise result from application of DMXB alone. Figure 6A shows fractional recovery of the control (acetylcholine) response when oocytes expressing wild-type alpha<sub>3</sub>beta<sub>4</sub> receptors were treated with DMXB alone (solid white bar, far left) or in the presence of metanicotine (cross-hatch bar, far right) (also shown in Figure 6A of Papke, 2002). Only co-application of metanicotine decreased the residual inhibition measured after application of DMXB. As is evident from the graph of Figure 3D of the patent application, if the recovery of the control response for metanicotine alone were to be presented in the bar graph of Figure 6A (*e.g.*, next to DMXB alone), it would show a response of approximately 1.0, neither activating nor inhibiting the alpha<sub>3</sub>beta<sub>4</sub> receptor. Thus, application of metanicotine does not just not inhibit the alpha<sub>3</sub>beta<sub>4</sub>

receptor, it actually protects the alpha3beta4 receptor from the residual inhibition that would otherwise occur upon application of DMXB or other mixed agonist-antagonists, such as ABT-418. This is not an additive effect.

Thus, if DMXB were given for the purpose of stimulating alpha3beta4 receptors in the CNS, concomitant treatment with metanicotine, which has virtually no effects on brain alpha3beta4 receptors (Papke 2000), would have a synergistic activity, reducing the peripheral side effects of DMXB alone. This ability of metanicotine to protect alpha3beta4 nAChR function from long-term inhibition by antagonists or mixed agonists-antagonists was not previously recognized in the scientific literature, and would not have been expected based upon the activities of metanicotine and the other compounds, individually.

As indicated in paragraph 0014 of the subject patent application, metanicotine's surprising ability to protect nAChR from the inhibitory after-effects of other potentially therapeutic compounds is of great clinical significance. For example, metanicotine can be co-administered with other potentially therapeutic mixed agonists-antagonists that may otherwise be disqualified for therapeutic use due to their inhibitory side effects. Most of the pharmacological effects that could potentially be avoided are those associated with blocking predominant tone of either the sympathetic or parasympathetic nervous system. The alpha3beta4 nAChR is important in both of these systems. Examples of such side effects include, but are not limited to, vasoconstriction, constipation, pupil dilation, xerostenia (dry mouth), loss of accommodation (focusing ability), urine hesitancy and retention, impotence, anorexia, eructation (belching), and orthostatic hypotension. Thus, co-administration of metanicotine with other compounds can provide a means to tune a spectrum of effects to enhance receptor subtype-selective activation, thereby providing a more positive profile of effects.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States


17

Docket No. UF-293  
Serial No. 10/036,988

Code and that such willful false statements may jeopardize the validity of the application or of any patent issuing thereon.


Further declarant sayeth naught.

Signed:



Roger L. Papke, Ph.D.

Date:






FIG. 6A




FIG. 6B